期刊文献+

去卵巢和抗骨质疏松干预后大鼠尿脱氧吡啶啉的变化 被引量:2

Changes of Urinary Deoxypyridinoline Crosslink/creatinine in Rats after Ovariectomy and Anti-osteoporotic Inter vention
下载PDF
导出
摘要 目的观察大鼠去卵巢及予以不同的干预后尿脱氧吡啶啉/肌酐比率(urinarydeoxypyridinolinecrosslink/creatinine,UDpd/Cr)的变化,了解其在骨质疏松的诊断和治疗中的应用价值。方法将40只Wister大鼠于6月龄时行去卵巢手术(OVX,n=32)和假手术(Sham,n=8)。手术后6周分别予以不同的干预如下:OVX组(Ovx,n=8)和Sham组不做干预;雌激素干预组(O+E,n=9)予以17β雌二醇20μg/(kg·d),皮下注射;英卡膦酸钠干预组(O+C,n=7)予以Cimadronate0.2mg/(kg·d),经胃肠给药。手术后14周将大鼠处死,处死前收集24h尿液和血液测定血清及尿液中生化指标;处死后留取右侧股骨标本,进行股骨外周定量CT骨密度及股骨远端凹入实验生物力学测定。结果OVX组大鼠的骨吸收指标UDpd/Cr比Sham组增加了133.3%(P<0.01),OVX组大鼠尿钙/肌酐比率亦有增加,但与Sham组相比差异无显著性(P>0.05)。雌激素和英卡膦酸钠干预组UDpd/Cr比OVX组显著降低,分别减少了54.6%和51.8%(P均<0.01),并与Sham组接近。UDpd/Cr与骨量、骨密度及骨生物力学等指标的相关分析表明,其与以上指标之间存在显著负相关。结论UDpd/Cr是敏感的骨吸收指标,在OVX和予以雌激素、二膦酸盐干预后均有显著变化,其改变与骨密度及骨骼力学特性的改变密切相关。 Objective To observe the changes of urinary deoxypyridinoline crosslink/creatinine(UDpd/Cr)in rats after OVX and intervention by estrogen and bisphosphonate and investigate the possible application of deoxypyridinoline in osteoporosis diagnosis and treatment.Methods 40female6-month-old virginal Wistar rats were divided into5groups,ovariectomized or sham ovariectomized.(1)Ovxb (n=8):sacrificed at6weeks after OVX;(2)Sham (n=8):sham ovariectomized;(3)Ovxe (n=8):sacrificed at14weeks after OVX;(4)O+E (n=9):OVX+17βestradiol[20μg/(kg·d)ih];(5)O+C(n=7):OVX+cimadronate [0.2mg /(kg·d)];Treatment started6weeks after OVX and lasted8weeks.Rats in group2~5were sacrificed at14weeks after OVX.Urinary and serum biochemical parameters were measured,pQCT scanning of femur,bone biomechanical test in femur were determined.Results OVX resulted in increasing of UDpd/Cr 133.3%(P<0.01).The ratio of UCa /Cr also increased in OVX groups but without any significant compared with Sham (P>0.05).UDpd/Cr were reduced by54.6%and51.8%(P<0.01)in O+E,O+C group respectively compared with Ovxe.The significant negative correlationships were found between UDpd/Cr and bone mass,BMD and biomechanic characteristics.Conclusions UDpd/Cr ratio is a sensitive bone resorption marker,a marked changes were observed when the rats ovariectomized or treated with estradiol and cimadronate.There were best correlation between UDpd/Cr and bone minral density and bone biomechanic characteristics.It is fair to apply UDpd/Cr ratio for osteoporosis diagnosis and treatment.
出处 《中国医学科学院学报》 CAS CSCD 北大核心 2003年第3期271-274,共4页 Acta Academiae Medicinae Sinicae
关键词 尿脱氧吡啶啉 骨吸收 去卵巢 大鼠 urinary deoxypyridinoline osteoporosis ovariectomy rats
  • 相关文献

参考文献16

  • 1夏维波,孟迅吾,邢小平,周学瀛,蒋颖,胡莹莹,刘怀成,林守清.戊酸雌二醇对去卵巢大鼠骨质疏松的治疗作用[J].中华妇产科杂志,2001,36(10):606-609. 被引量:9
  • 2夏维波,孟迅吾,周学瀛,邢小平,胡莹莹,刘怀成,邱贵兴,Victor Shen.英卡膦酸钠对去卵巢大鼠骨质疏松的作用[J].中华内分泌代谢杂志,2002,18(2):103-107. 被引量:1
  • 3World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.WHO Technical Report Series. Geneva: WHO, 1994. 843.
  • 4Ouillon R, Burkhardt P, Christiansen C, et al. Concensus development conference: prophylaxis and treatment of osteoporosis. Osteoporosis Int, 1991, 1:114-117.
  • 5Zhan Z, Yamamoto I, Morita R. Urinary pyridinoline and deoxypyridinoline as bone metabolic markers in predicting therapeutie effects of estrogen and alfacaleidol in women with osteoporesis. J Bone Miner Metab, 1999, 17(2):113-118.
  • 6Bauer DC, Black DM, Gamero P, et al. Reduction in bone tumover predicts hip, non-spine, and vertebral fracture in alendronate treated women: the fracture intervention trial.J Bone Miner Res, 2002, 17(suppl 1):S187.
  • 7Pardini DP, Sabino AT, Meneses AM, et al. Effect of hormone replacement therapy on the bone mass and urinary excretion of pyddinium cross-links. Sao Paulo Med J,2000, 118(1):3-6.
  • 8Meng XW, Liang GX, Birchman R, et al.Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J Bone Miner Res,421-429.
  • 9Elzi R, Zampino M, Soldarini A, et al. Total and free deoxypyxidinoline after acute osteoclut activity inhibition.Clin Chem, 1999, 45(9):1510-1516.
  • 10Frost HM, Jee W SS. On the rat model of human osteopenias and osteoporoses. Bone Miner, 1992, 18:227-236.

二级参考文献18

  • 1Chow J,Tobias J H,Colston KW,et al.Estrogen maintain trabecular bone volum in rats not only by suppression of bone resorption but also by stimulation of bone formation[].The Journal of Clinical Investigation.1992
  • 2Editor.Histomorphometric terminology, appendix D[].Calcified Tissue International.1998
  • 3Fuse H,Fukumoto S,Sone H,et al.A new steriod, osaterone acetate(TZP-4238), increase cortical bone mas s and strength by enhancing bone formation in ovariectomized rats[].Journal of Bone and Mineral Research.1997
  • 4Christiansen C,Christeinsen MS,Larsen NE,et al.Pathophysiological mechanisms of estrogen effect on bone metabolism.Dose-response relationships in early postmenopausal women[].The Journal of Clinical Endocrinology.1982
  • 5Steiniche T,Hasling C,Charles P,et al.Randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis[].Bone.1989
  • 6Wronski TJ,Cintron M,Doherty AL,et al.Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats[].The Journal of Endocrinology.1988
  • 7Sims NA,Morris HA,Moore RJ,et al.Estradiol treatment transiently increases trabecular bone volume in ovariectomized rats[].Bone.1996
  • 8Kanis J A.Treatment of osteoporotic fracture[].The Lancet.1984
  • 9Devogelaer JP,Broll H,Correa-Rotter R,et al.Oral alendronate induces progressive increase in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis[].Bone.1996
  • 10Nij A,Fujimoto R,Okazaki A,et al.Intramembranous and endochondral bone changes induced by a new bisphosphonate(YM175) in the beagle dog[].Toxicologic Pathology.1994

共引文献8

同被引文献14

  • 1丁桂芝,曾天舒,周勇,李榕.补肾中药对去势大鼠骨生物力学影响的研究[J].中国中医骨伤科,1995,3(1):1-3. 被引量:42
  • 2NIH consensus development panel on osteoporosis prevention,diagnosis,and therapy.Osteoporosis prevention,diagnosis,and therapy.JAMA,2001,285:785-795.
  • 3Watts NB.Bone quality:getting closer to a definition.J Bone Miner Res,2002,17:1148-1150.
  • 4Cummings SR,Karpf DB,Harris F,et al.Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.Am J Med,2002,112:281-289.
  • 5Turner CH.Biomechanics of bone:determinants of skeletal fragility and bone quality.Osteoporos Int,2002,13:97-104.
  • 6Garnero P,Malmann D,Munoz F,et al.Long-term variability of bone markers of bone turnover in postmenopausal women and implicalions for their clinical utility.J Bone Miner Res,2002,17(Suppl 1) S299.
  • 7Eastell R,Barton I,Hannon RA,et al.Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.J Bone Miner Res,2003,18:1051-1056.
  • 8Delmas PD.How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone,2000,27:1-3.
  • 9Susan L,Greenspa N,Neil M,et al.Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate,hormone replacement therapy,or combination therapy:a three-year,double-blind,placebo-controlled,randomized clinical trial.J Clin Endo Metab,90:2762-2767.
  • 10夏维波,孟迅吾,胡莹莹,刘怀成,秦明伟,余卫,邢小平,田均平,周学瀛.阿伦膦酸钠防治原发性骨质疏松症的疗效观察[J].中国实用内科杂志,2000,20(4):214-216. 被引量:1

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部